menu search

Spexis provides business update and announces financial results for the full year 2022

Spexis provides business update and announces financial results for the full year 2022
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in mid-2023 Reported solid safety and pharmacokinetics results from first-in-human study of inhaled murepavadin Announced positive renal impairment clinical trial results with balixafortide ALLSCHWIL, Switzerland, May 29, […] The post Spexis provides business update and announces financial results for the full ye... Read More
Posted: May 30 2023, 05:15
Author Name: forextv
Views: 101978

Search within

Pages Search Results: